Matches in SemOpenAlex for { <https://semopenalex.org/authorship/W2564614797A5026349633> ?p ?o ?g. }
Showing items 1 to 18 of
18
with 100 items per page.
- W2564614797A5026349633 type Authorship @default.
- W2564614797A5026349633 hasAuthor A5026349633 @default.
- W2564614797A5026349633 hasOrganization I180857899 @default.
- W2564614797A5026349633 hasOrganization I4210086790 @default.
- W2564614797A5026349633 hasOrganization I4210095529 @default.
- W2564614797A5026349633 hasOrganization I4210099842 @default.
- W2564614797A5026349633 hasOrganization I4210114143 @default.
- W2564614797A5026349633 hasOrganization I4210115949 @default.
- W2564614797A5026349633 hasOrganization I4210116173 @default.
- W2564614797A5026349633 hasOrganization I4210119467 @default.
- W2564614797A5026349633 hasOrganization I4210129180 @default.
- W2564614797A5026349633 hasOrganization I4210143693 @default.
- W2564614797A5026349633 hasOrganization I4210150276 @default.
- W2564614797A5026349633 hasOrganization I4210153460 @default.
- W2564614797A5026349633 hasOrganization I4210158107 @default.
- W2564614797A5026349633 isCorresponding "false" @default.
- W2564614797A5026349633 position "13" @default.
- W2564614797A5026349633 rawAffiliation "***Private Practice Fischbach, North-Rhine, Solingen, Germany; **Pediatrics Department, Rio Hortega University Hospital, Valladolid, Spain; Accepted for publication September 12, 2016.; From the *Pediatrics Department, Hospital Universitario de Burgos, Avenida Islas Baleares, Burgos, Spain; GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also funded all costs associated with the development and the publishing of the present manuscript. A.C.M. declares financial support from “Fundación Médica Alfonso Carmona.” J.M.M.A. received fees for consulting, lectures and expert testimony from the GSK group of companies. X.M.P.P. was a speaker, researcher and consultant for the GSK group of companies. J.M.B. serves on the Board of Sanofi Pasteur MSD and has received fees from Sanofi Pasteur MSD (for lectures including service on speakers bureaus), from the GSK group of companies (for lectures including service on speakers bureaus and as a principal investigator in clinical trials), from Pfizer (as a principal investigator in clinical trials, for lectures including service on speakers bureaus). M.H. received consulting fees from the GSK group of companies and Novartis; NIMENRIX, SYNFLORIX, INFANRIX HEXA, MENJUGATE and MENVEO are trademarks of the GSK Group of Companies. NEISVAC-C is a registered trademark of Pfizer. NIMENRIX trademark has been licensed to Pfizer.; Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.pidj.com).; payment for board membership from Novartis; payment for lectures including service on speakers bureaus, development of educational presentations, and travel, accommodation and meeting expenses from the GSK group of companies, Sanofi Pasteur MSD and Novartis. D.K. and M.W. are employees of the GSK group of companies. Y.B. was an employee of the GSK group of companies at the time of the study. Y.B. and M.W. declared stock ownership in the GSK group of companies. The other authors have no conflicts of interest to disclose.; support for travel to meetings for the study from the GSK group of companies; §Manlleu Primary Care Center, Osona, Spain; §§Hospital General Universitario de Ciudad Real, Ciudad Real, Spain; §§§GSK Vaccines, Merion, Pennsylvania.; ¶Pediatrics Department, Hospital La Fe, Valencia, Spain; ¶¶Study Center Weilheim, Pediatric Practice Weilheim, Weilheim in Oberbayern, Germany; ‖Institut Pediàtric Marès – Riera, Pediatría, Blanes, Spain; ‖‖Private Practice Bleckmann, Baunatal, Germany; †Instituto Hispalense de Pediatria, C/Jardin de la Isla N° 6, Edificio Expolocal, Sevilla, Spain; ††Pediatrics Department, Hospital de Antequera, Antequera, Spain; ‡Pediatric Office Dr. Horn, Schoenau, Germany; ‡‡Hospital Universitari Germans Trias i Pujol, Badalona, Spain; ‡‡‡GSK Vaccines, Vaccine Development and Discovery Department, Wavre, Belgium" @default.